The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2015 | The promise of second-generation PI3K inhibitors for CLL
John Gribben and Stephan Stilgenbauer
• 4 Dec 2015
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.
